{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T01:34:02Z","timestamp":1759541642130,"version":"3.41.0"},"reference-count":18,"publisher":"Japanese Society of Internal Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2018]]},"DOI":"10.2169\/internalmedicine.9216-17","type":"journal-article","created":{"date-parts":[[2017,10,15]],"date-time":"2017-10-15T22:09:55Z","timestamp":1508105395000},"page":"53-57","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy of Oxycodone for Dyspnea in End-stage Heart Failure with Renal Insufficiency"],"prefix":"10.2169","volume":"57","author":[{"given":"Masayuki","family":"Tanaka","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Kansai Medical University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Maeba","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine II, Kansai Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Senoo","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine II, Kansai Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Iwasaka","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine II, Kansai Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aki","family":"Ohkita","sequence":"additional","affiliation":[{"name":"Department of Nursing, Kansai Medical University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruna","family":"Kita","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kansai Medical University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Uchitani","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kansai Medical University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiko","family":"Hirota","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kansai Medical University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Goodlin SJ. Palliative care in congestive heart failure. J Am Coll Cardiol 54: 386-396, 2009.","DOI":"10.1016\/j.jacc.2009.02.078"},{"key":"2","unstructured":"2. Murray SA, Boyd K, Kendall M, Worth A, Benton TF, Clausen H. Dying of lung cancer or cardiac failure: prospective qualitative interview study of patients and their carers in the community. BMJ 325: 929, 2002."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Kelley AS, Morrison RS. Palliative care for the seriously ill. N Engl J Med 373: 747-755, 2015.","DOI":"10.1056\/NEJMra1404684"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Hochgerner M, Fruhwald FM, Strohscheer I. Opioids for symptomatic therapy of dyspnoea in patients with advanced chronic heart failure-is there evidence? Wien Med Wochenschr 159: 577-582, 2009 (in German, Abstract in English).","DOI":"10.1007\/s10354-009-0726-0"},{"key":"5","unstructured":"5. Jennings AL, Davies AN, Higgins JP, Anzures-Cabrera J, Broadley KE. WITHDRAWN: Opioids for the palliation of breathlessness in advanced disease and terminal illness. Cochrane Database Syst Rev 7: CD002066, 2012."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Johnson MJ, McDonagh TA, Harkness A, McKay SE, Dargie HJ. Morphine for the relief of breathlessness in patients with chronic heart failure-a pilot study. Eur J Heart Fail 4: 753-756, 2002.","DOI":"10.1016\/S1388-9842(02)00158-7"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 14: 377-381, 1982.","DOI":"10.1249\/00005768-198205000-00012"},{"key":"8","unstructured":"8. Oxberry SG, Torgerson DJ, Bland JM, Clark AL, Cleland JG, Johnson MJ. Short-term opioids for breathlessness in stable chronic heart failure: a randomized controlled trial. Eur J Heart Fail 13: 1006-1012, 2011."},{"key":"9","unstructured":"9. Peacock WF, Hollander JE, Diercks DB, Lopatin M, Fonarow G, Emerman CL. Morphine and outcomes in acute decompensated heart failure: an ADHERE analysis. Emerg Med J 25: 205-209, 2008."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Hasselstr\u00f6m J, S\u00e4we J. Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations. Clin Pharmacokinet 24: 344-354, 1993.","DOI":"10.2165\/00003088-199324040-00007"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Pasternak GW, Bodnar RJ, Clark JA, Inturrisi CE. Morphine-6-glucuronide, a potent mu agonist. Life Sci 41: 2845-2849, 1987.","DOI":"10.1016\/0024-3205(87)90431-0"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Frances B, Gout R, Monsarrat B, Cros J, Zajac JM. Further evidence that morphine-6 beta-glucuronide is a more potent opioid agonist than morphine. J Pharmacol Exp Ther 262: 25-31, 1992.","DOI":"10.1097\/00132586-199304000-00005"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Paul D, Standifer KM, Inturrisi CE, Pasternak GW. Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite. J Pharmacol Exp Ther 251: 477-483, 1989.","DOI":"10.1016\/S0022-3565(25)20832-1"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Romberg R, Sarton E, Teppema L, Matthes HW, Kieffer BL, Dahan A. Comparison of morphine-6-glucuronide and morphine on respiratory depressant and antinociceptive responses in wild type and mu-opioid receptor deficient mice. Br J Anaesth 91: 862-870, 2003.","DOI":"10.1093\/bja\/aeg279"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Fonarow GC, Heywood JT. The confounding issue of comorbid renal insufficiency. Am J Med 119: S17-S25, 2006.","DOI":"10.1016\/j.amjmed.2006.09.013"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. P\u00f6yhi\u00e4 R, Olkkola KT, Sepp\u00e4l\u00e4 T, Kalso E. The pharmacokinetics of oxycodone after intravenous injection in adults. Br J Clin Pharmacol 32: 516-518, 1991.","DOI":"10.1111\/j.1365-2125.1991.tb03942.x"},{"key":"17","unstructured":"17. Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen LY, Shen DD. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther 79: 461-479, 2006."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Oxberry SG, Bland JM, Clark AL, Cleland JG, Johnson MJ. Repeat dose opioids may be effective for breathlessness in chronic heart failure if given for long enough. J Palliat Med 16: 250-255, 2013.","DOI":"10.1089\/jpm.2012.0270"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/1\/57_9216-17\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T14:02:20Z","timestamp":1750946540000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/1\/57_9216-17\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.9216-17","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"type":"print","value":"0918-2918"},{"type":"electronic","value":"1349-7235"}],"subject":[],"published":{"date-parts":[[2018]]}}}